FDA extends review of AstraZeneca/BMS experimental diabetes drug Onglyza.
Teva blocked from launching generic form of Lilly‘s Evista; also rumored to be eyeballing a purchase of Watson.
Roche/Genentech‘s Avastin misses the mark in colon cancer study.
PLUS – you want pharma growth? Sanofi says, Go East! (I know another big pharma also ramping up very rapidly in China…)
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff
Leave a Reply